GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (FRA:04I) » Definitions » Debt-to-Revenue

InVivo Therapeutics Holdings (FRA:04I) Debt-to-Revenue : N/A (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is InVivo Therapeutics Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

InVivo Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.00 Mil. InVivo Therapeutics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.00 Mil. InVivo Therapeutics Holdings's annualized Revenue for the quarter that ended in Sep. 2023 was €0.00 Mil.


InVivo Therapeutics Holdings Debt-to-Revenue Historical Data

The historical data trend for InVivo Therapeutics Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings Debt-to-Revenue Chart

InVivo Therapeutics Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

InVivo Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of InVivo Therapeutics Holdings's Debt-to-Revenue

For the Biotechnology subindustry, InVivo Therapeutics Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's Debt-to-Revenue falls into.



InVivo Therapeutics Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

InVivo Therapeutics Holdings's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.374 + 0.522) / N/A
=N/A

InVivo Therapeutics Holdings's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2023) Revenue data.


InVivo Therapeutics Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (FRA:04I) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

InVivo Therapeutics Holdings (FRA:04I) Headlines

No Headlines